CAPRI 2 GOIM study: investigate the efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wt tumors at start of first line.
Ontology highlight
ABSTRACT: Primary objectives: Response Rate (RR) per each line of therapy: assessed according to RECIST criteria 1.1
Primary endpoints: Response Rate (RR) per each line of therapy assessed according to RECIST criteria 1.1
DISEASE(S): Metastatic Colorectal Cancer,Pazienti Affetti Da Carcinoma Del Colonretto Metastatico Che Presentano Uno Stato Wild Type Di Ras E Braf Prima Dell’inizio Del Trattamento Di Prima Linea,Mcrc Patients With Ras/braf Wild Type Tumors At Start Of First Line Treatment
PROVIDER: 2540493 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA